The Merlini, Waldenström, Jayakar staging system revisited
- 1 December 1989
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 43 (S51), 105-110
- https://doi.org/10.1111/j.1600-0609.1989.tb01501.x
Abstract
At present, none of the routinely used staging systems is entirely satisfactory, since all of them require some reconsideration to account for the most recent prognostic factors. Among these, serum beta-2 microglobulin (S-beta-2M) has proved to be a powerful prognostic test assessable in most centers. In order to improve the Merlini, Waldenström, Jayakar (MWJ) staging system, we have determined the prognostic significance of several factors in an independent population of 345 retrospective myeloma patients seen at our institution from 1973 to 1988. The Cox regression hazards method showed that S-Creatinine, S-Albumin levels and percentage of bone marrow plasma cells accounted for 94% of total chi 2 achieved with all eight variables (including also: paraprotein index, S-Calcium, S-M-component, bone lesions and hemoglobin). The same analysis, applied to patients in whom S-beta-2M was available at presentation, selected S-beta-2M, S-Creatinine and percentage of bone marrow plasma cells (accounting for 92% of total chi 2), followed by platelet count, S-Albumin and S-M-component. The best discriminatory level of S-beta-2M was found to be 4 mg/l. However, the prognostic power of S-beta-2M when used with binary values was remarkably reduced with respect to its application as a continuous variable. In patients with MWJ stage 1 and 2 disease, S-beta-2M had an independent prognostic significance. Grouping stage I and II patients with S-beta-2M less than or more than 4 mg/l presented a median survival of 70 and 40 months, respectively. In stage 3 patients S-beta-2M did not contribute additional prognostic information.(ABSTRACT TRUNCATED AT 250 WORDS)Keywords
This publication has 36 references indexed in Scilit:
- Multiple myeloma: Relationship between light chain isotype suppression, labelling index of plasma cells, and CD38 expression on peripheral blood lymphocytesAmerican Journal of Hematology, 1988
- Biochemical markers in multiple myeloma: a multivariate analysisBritish Journal of Haematology, 1988
- Prognostic factors and staging systems for multiple myeloma: Comparisons between the medical research council studies in the United Kingdom and the Southwest oncology group studies in the United StatesHematological Oncology, 1988
- IMMUNOREGULATION AND PROGNOSIS IN MYELOMAThe Lancet, 1987
- Pretreatment serum β2‐microglobulin in multiple myelomaBritish Journal of Haematology, 1985
- Serum beta2‐microglobulin: a real improvement in the management of multiple myeloma?British Journal of Haematology, 1985
- Evaluation of serum deoxythymidine kinase as a marker in multiple myelomaBritish Journal of Haematology, 1985
- Serum beta2 microglobulin and survival duration in multiple myeloma: a simple reliable marker for staging.British Journal of Haematology, 1983
- Critical Study of Staging in Multiple MyelomaScandinavian Journal of Haematology, 1983
- Prognostic Value of the Staging System Proposed by Merlini, Waldenström and Jayakar for Multiple MyelomaActa Haematologica, 1983